ASPIRIN; DIPYRIDAMOLE - Generic Drug Details

What are the generic sources for aspirin; dipyridamole and what is the scope of freedom to operate?

Aspirin; dipyridamole is the generic ingredient in two branded drugs marketed by Boehringer Ingelheim, Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Glenmark Speclt, Micro Labs, Ph Health, Sandoz, Sun Pharm, and Zydus Pharms, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

Nine suppliers are listed for this compound.

Summary for ASPIRIN; DIPYRIDAMOLE

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	12
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	25
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ASPIRIN; DIPYRIDAMOLE
DailyMed Link:	ASPIRIN; DIPYRIDAMOLE at DailyMed

Recent Clinical Trials for ASPIRIN; DIPYRIDAMOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	Phase 3
Région Hauts de France, France	Phase 3
Ministry of Health, France	Phase 3

See all ASPIRIN; DIPYRIDAMOLE clinical trials

Pharmacology for ASPIRIN; DIPYRIDAMOLE

Drug Class	Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Decreased Platelet Aggregation Decreased Prostaglandin Production

Anatomical Therapeutic Chemical (ATC) Classes for ASPIRIN; DIPYRIDAMOLE

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for ASPIRIN; DIPYRIDAMOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AGGRENOX	Extended-release Capsules	aspirin; dipyridamole	25 mg and 200 mg	020884	1	2007-02-01

US Patents and Regulatory Information for ASPIRIN; DIPYRIDAMOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	206739-001	Jan 18, 2017	AB	RX	No	No
Ani Pharms	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	206964-001	Jan 18, 2017		DISCN	No	No
Boehringer Ingelheim	AGGRENOX	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	020884-001	Nov 22, 1999		DISCN	Yes	No
Glenmark Speclt	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	210318-001	May 24, 2019	AB	RX	No	Yes
Micro Labs	ASPIRIN AND DIPYRIDAMOLE	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	209929-001	Aug 11, 2021	AB	RX	No	No

Expired US Patents for ASPIRIN; DIPYRIDAMOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	AGGRENOX	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	020884-001	Nov 22, 1999	6,015,577

ASPIRIN; DIPYRIDAMOLE Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics and Financial Trajectory for Aspirin and Dipyridamole

Aspirin and dipyridamole are well-established drugs with distinct roles in cardiovascular therapy. Aspirin's global market is characterized by high consumer penetration and generic availability, while dipyridamole occupies niche segments, primarily in secondary stroke prevention.

---

Market Overview

Aspirin

• Global Market Size: Estimated at $2.5 billion in 2022. Projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2027.
• Key Markets: United States, China, India, European Union.
• Usage: Over-the-counter (OTC) and prescription, primarily for pain relief, fever reduction, and cardiovascular prophylaxis.
• Generics: Dominates sales; branded versions (e.g., Bayer Aspirin) account for less than 10% market share.
• Regulatory Landscape: U.S. FDA approved aspirin as an over-the-counter drug for cardiovascular use in 2014, further expanding accessibility.
• Competition: From newer antiplatelet agents (clopidogrel, ticagrelor), but aspirin maintains relevance due to cost-effectiveness.

Dipyridamole

• Market Size: Approximately $150 million in 2022.
• Key Markets: Europe (mainly UK, Germany), limited sales in the U.S.
• Usage: Prescribed for secondary stroke prevention, often in combination with other antiplatelet agents such as aspirin.
• Formulation: Oral tablets, with some formulations combined with aspirin.
• Regulatory Status: Approved in multiple countries; U.S. market authorization withdrew in 2004, though still marketed in Europe.
• Competition: Other antiplatelet drugs and anticoagulants like warfarin, NOACs (e.g., apixaban).

---

Market Drivers and Challenges

Aspirin

• Drivers:

  • Established safety profile.
  • Cost-effective for large populations.
  • Growing acceptance for primary and secondary prevention.

• Challenges:

  • Bleeding risks limit use in some patient groups.
  • Competition from newer antiplatelet and anticoagulant medications.
  • Regulatory updates on indications reduce off-label use.

Dipyridamole

• Drivers:

  • Favorable safety profile.
  • Used adjunctively with aspirin for stroke prevention.

• Challenges:

  • Limited market due to reduced regulatory approval in key regions (U.S.).
  • Competition from NOACs and other antiplatelet agents.
  • Limited innovation, as it remains a generic with no significant patent barriers.

---

Financial Trajectory and Trends

Drug	Current Market (2022)	CAGR (2023–2027)	Key Growth Factors	Market Limitations
Aspirin	$2.5 billion	4%	Aging population, cardiovascular disease prevalence	Competition, regulatory restrictions
Dipyridamole	$150 million	2-3%	Niche role in stroke prevention	Market shrinking in the U.S., generic competition

Aspirin's market growth benefits from expanding indications and high-volume OTC sales. However, safety concerns and regulatory adjustments may temper growth. Dipyridamole's market remains stable but limited, constrained by regional approvals and the dominance of newer alternatives.

---

Regulatory and Patent Landscape

Aspirin

• Patents have expired, with the last patent expiring around 1980, leading to widespread generic manufacturing.
• Regulatory agencies have issued guidelines about appropriate use, especially for cardiovascular prophylaxis, affecting prescribing practices.

Dipyridamole

• Patent status: Expired in most markets.
• Regulatory fluctuations: U.S. withdrawal in 2004, but approval persists elsewhere.
• No recent new formulations or modifications to extend exclusivity.

---

Strategic Outlook

For Aspirin:

• Despite generic status, potential growth exists via novel formulations (e.g., extended-release), combination therapies, and targeted indications.
• Emphasis on compliance with evolving clinical guidelines could influence market size.

For Dipyridamole:

• Market growth hinges on renewed regulatory approval in large markets like the U.S.
• Positioning as an adjunct in combined therapies could foster incremental demand.

---

Key Takeaways

• Aspirin dominates nearly $2.5 billion global market, with steady growth driven by brand extensions and expanded indications.
• Dipyridamole holds a niche market (~$150 million), mainly in Europe, with limited prospects in the U.S.
• Competitive landscape shifts, especially for aspirin, are driven by newer agents and safety considerations.
• Market expansion opportunities are tied to formulation innovation and regulatory environment changes.
• Patent expirations have flattened direct revenue streams, focusing competition on price and formulation.

---

FAQs

1. Will aspirin’s market decline due to safety concerns?
While safety issues, primarily bleeding risks, have led to more cautious use, the large volume of OTC sales sustains its market. Formulations with improved safety profiles or targeted indications may mitigate decline.

2. Is there potential for dipyridamole in the U.S. market?
Yes. Gaining regulatory approval could reinvigorate demand, especially in combination therapies for stroke prevention.

3. How do newer antiplatelet drugs impact aspirin?
Newer agents offer lower bleeding risks or easier dosing, reducing aspirin’s dominance for some indications but not fully replacing its economic advantage.

4. Are there ongoing research efforts to extend aspirin’s patent life?
Limited, mainly in combination formulations or novel delivery routes, which may command premium pricing but face regulatory hurdles.

5. What market segments could expand for both drugs?
Preventive cardiovascular care and secondary stroke prevention, especially in aging populations with high cardiovascular risk.

---

References

1. GlobalData. "Aspirin Market Report 2022."
2. IQVIA. "Pharmaceutical Market Observations, 2022."
3. European Medicines Agency. "Dipyridamole Regulatory Status."
4. U.S. Food & Drug Administration. "Aspirin Approval and Usage Guidelines."
5. Analyze Pharma. "Cardiovascular Drug Market Trends 2023."